Literature DB >> 10483531

Estimation of active conformations of drugs by a new molecular superposing procedure.

K Iwase1, S Hirono.   

Abstract

We have developed a new program, SUPERPOSE, to superpose two molecules based on the physicochemical properties of functional atoms within individual molecules. SUPERPOSE treats a pseudo-molecule consisting of functional atoms instead of a real molecule. Four types of physicochemical properties--hydrophobicity, presence of a hydrogen-bonding donor, presence of a hydrogen-bonding acceptor and presence of a hydrogen-bonding donor/acceptor--were supposed and a score was given to each overlap. When functional atoms with the same physicochemical properties were overlapped, points were added to the score, and when the functional atoms with different physicochemical properties were overlapped, points were subtracted. We applied SUPERPOSE to 12 pairs of 24 enzyme inhibitors and found that the best scored overlay for each inhibitor pair could successfully reproduce the superposition obtained from X-ray crystallography. Next, we applied SUPERPOSE to estimate the active conformations of the thrombin inhibitors MQPA, 4-TAPAP and NAPAP. Superpositions of conformers sampled by the high-temperature molecular dynamics calculation with respect to the three inhibitors were performed, and 13 sets of conformers having the best common overlay to the three inhibitors were selected. One among 13 sets was consistent with the superposition of the active conformations derived from the X-ray crystallography of the thrombin-inhibitor complexes.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10483531     DOI: 10.1023/a:1008011422113

Source DB:  PubMed          Journal:  J Comput Aided Mol Des        ISSN: 0920-654X            Impact factor:   3.686


  7 in total

1.  QXP: powerful, rapid computer algorithms for structure-based drug design.

Authors:  C McMartin; R S Bohacek
Journal:  J Comput Aided Mol Des       Date:  1997-07       Impact factor: 3.686

2.  Molecular surface-volume and property matching to superpose flexible dissimilar molecules.

Authors:  T D Perkins; J E Mills; P M Dean
Journal:  J Comput Aided Mol Des       Date:  1995-12       Impact factor: 3.686

3.  CAMDAS: an automated conformational analysis system using molecular dynamics. Conformational Analyzer with Molecular Dynamics And Sampling.

Authors:  H Tsujishita; S Hirono
Journal:  J Comput Aided Mol Des       Date:  1997-05       Impact factor: 3.686

Review 4.  Accurate simulation of protein dynamics in solution.

Authors:  M Levitt; R Sharon
Journal:  Proc Natl Acad Sci U S A       Date:  1988-10       Impact factor: 11.205

5.  Enzymes work by solvation substitution rather than by desolvation.

Authors:  A Warshel; J Aqvist; S Creighton
Journal:  Proc Natl Acad Sci U S A       Date:  1989-08       Impact factor: 11.205

6.  Flexible matching of test ligands to a 3D pharmacophore using a molecular superposition force field: comparison of predicted and experimental conformations of inhibitors of three enzymes.

Authors:  C McMartin; R S Bohacek
Journal:  J Comput Aided Mol Des       Date:  1995-06       Impact factor: 3.686

7.  A fast new approach to pharmacophore mapping and its application to dopaminergic and benzodiazepine agonists.

Authors:  Y C Martin; M G Bures; E A Danaher; J DeLazzer; I Lico; P A Pavlik
Journal:  J Comput Aided Mol Des       Date:  1993-02       Impact factor: 3.686

  7 in total
  3 in total

1.  In silico fragment-mapping method: a new tool for fragment-based/structure-based drug discovery.

Authors:  Noriyuki Yamaotsu; Shuichi Hirono
Journal:  J Comput Aided Mol Des       Date:  2018-09-08       Impact factor: 3.686

2.  Estimation of the three-dimensional pharmacophore of ligands for rat multidrug-resistance-associated protein 2 using ligand-based drug design techniques.

Authors:  Shuichi Hirono; Izumi Nakagome; Rie Imai; Kazuya Maeda; Hiroyuki Kusuhara; Yuichi Sugiyama
Journal:  Pharm Res       Date:  2005-02       Impact factor: 4.200

3.  AMF-26, a novel inhibitor of the Golgi system, targeting ADP-ribosylation factor 1 (Arf1) with potential for cancer therapy.

Authors:  Yoshimi Ohashi; Hiroshi Iijima; Noriyuki Yamaotsu; Kanami Yamazaki; Shigeo Sato; Mutsumi Okamura; Kenji Sugimoto; Shingo Dan; Shuichi Hirono; Takao Yamori
Journal:  J Biol Chem       Date:  2011-12-09       Impact factor: 5.157

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.